Podoplanin (PDPN) obtained from various animal species has been characterized using specific anti-PDPN monoclonal antibodies (mAbs), namely, PMab-1, PMab-2, PMab-32, PMab-38, PMab-44, and PMab-52 against mouse, rat, rabbit, dog, bovine, and cat PDPN, respectively. PDPN is expressed in type I alveolar cells in lungs, lymphatic endothelial cells, and kidney podocytes. In this study, we investigated possible cross-reactions between anti-PDPN mAbs and sheep PDPN. Type I alveolar cells from sheep lung were strongly detected by PMab-44 using immunohistochemical analyses. These results indicate that PMab-44 may be useful for the detection of sheep PDPN.
Get full access to this article
View all access options for this article.
References
1.
KanekoMK, KatoY, KitanoT, and OsawaM: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 2006; 378:52–57.
2.
KatoY, FujitaN, KunitaA, SatoS, KanekoM, OsawaM, and TsuruoT: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem, 2003; 278:51599–51605.
3.
KanekoM, KatoY, KunitaA, FujitaN, TsuruoT, and OsawaM: Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/podoplanin) molecules expressed in Chinese Hamster Ovary cells. J Biol Chem, 2004; 279:38838–38843.
4.
SekiguchiT, TakemotoA, TakagiS, TakatoriK, SatoS, TakamiM, and FujitaN: Targeting a novel domain in podoplanin for inhibiting plateletmediated tumor metastasis. Oncotarget, 2016; 7:3934–3946.
5.
Martin-VillarE, MegiasD, CastelS, YurritaMM, VilaroS, and QuintanillaM: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci, 2006; 119:4541–4553.
6.
Martin-VillarE, Fernandez-MunozB, ParsonsM, YurritaMM, MegiasD, Perez-GomezE, JonesGE, and QuintanillaM: Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell, 2010; 21:4387–4399.
7.
Martin-VillarE, Borda-d'AguaB, Carrasco-RamirezP, RenartJ, ParsonsM, QuintanillaM, and JonesGE: Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability. Oncogene, 2015; 34:4531–4544.
8.
Breiteneder-GeleffS, SoleimanA, KowalskiH, HorvatR, AmannG, KriehuberE, DiemK, WeningerW, TschachlerE, AlitaloK, and KerjaschkiD: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol, 1999; 154:385–394.
9.
KajiC, TsujimotoY, Kato KanekoM, KatoY, and SawaY: Immunohistochemical examination of novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem Cytochem, 2012; 45:227–237.
10.
OkiH, HonmaR, OgasawaraS, FujiiY, LiuX, TakagiM, KanekoMK, and KatoY: Development of sensitive monoclonal antibody PMab-2 against rat podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:396–403.
11.
HonmaR, FujiiY, OgasawaraS, OkiH, LiuX, NakamuraT, KanekoMK, TakagiM, and KatoY: Establishment of a novel monoclonal antibody PMab-32 against rabbit podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:41–47.
12.
HonmaR, KanekoMK, OgasawaraS, FujiiY, KonnaiS, TakagiM, and KatoY: Specific detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal antibody PMab-38 in immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2016; 35:212–216.
13.
YamadaS, ItaiS, KanekoMK, and KatoY: PMab-48 recognizes dog podoplanin of lymphatic endothelial cells. Monoclon Antib Immunodiagn Immunother, 2018; 37:63–66.
OgasawaraS, HonmaR, KanekoMK, FujiiY, KagawaY, KonnaiS, and KatoY: Podoplanin expression in canine melanoma. Monoclon Antib Immunodiagn Immunother, 2016; 35:304–306.
18.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
19.
KatoY, KunitaA, AbeS, OgasawaraS, FujiiY, OkiH, FukayamaM, NishiokaY, and KanekoMK: The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget, 2015; 6:36003–36018.
20.
OgasawaraS, OkiH, KanekoMK, HozumiY, LiuX, HonmaR, FujiiY, NakamuraT, GotoK, TakagiM, and KatoY: Development of monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:318–326.
21.
OgasawaraS, KanekoMK, HonmaR, OkiH, FujiiY, TakagiM, SuzukiH, and KatoY: Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:155–162.
22.
KatoY, OgasawaraS, OkiH, HonmaR, TakagiM, FujiiY, NakamuraT, SaidohN, KannoH, UmetsuM, KamataS, KuboH, YamadaM, SawaY, MoritaK, HaradaH, SuzukiH, and KanekoMK: Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:109–116.
23.
KatoY, OgasawaraS, OkiH, GoichbergP, HonmaR, FujiiY, and KanekoMK: LpMab-12 established by CasMab technology specifically detects sialylated O-Glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin. PLoS One, 2016; 11:e0152912.
24.
OgasawaraS, KanekoMK, and KatoY: LpMab-19 recognizes sialylated O-Glycan on Thr76 of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:245–253.
25.
KanekoMK, NakamuraT, HonmaR, OgasawaraS, FujiiY, AbeS, TakagiM, HaradaH, SuzukiH, NishiokaY, and KatoY: Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med, 2017; 6:382–396.
26.
KatoY, KunitaA, FukayamaM, AbeS, NishiokaY, UchidaH, TaharaH, YamadaS, YanakaM, NakamuraT, SaidohN, YoshidaK, FujiiY, HonmaR, TakagiM, OgasawaraS, MurataT, and KanekoMK: Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Monoclon Antib Immunodiagn Immunother, 2017; 36:20–24.
27.
KanekoMK, YamadaS, NakamuraT, AbeS, NishiokaY, KunitaA, FukayamaM, FujiiY, OgasawaraS, and KatoY: Antitumor activity of chLpMab-2, a human–mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med, 2017; 6:768–777.
28.
YamadaS, KanekoMK, and KatoY: LpMab-23: A cancer-specific monoclonal antibody against human podoplanin. Monoclon Antib Immunodiagn Immunother, 2017; 36:72–76.
YamadaS, HonmaR, KanekoMK, NakamuraT, YanakaM, SaidohN, TakagiM, KonnaiS, and KatoY: Characterization of the anti-bovine podoplanin monoclonal antibody PMab-44. Monoclon Antib Immunodiagn Immunother, 2017; 36:129–134.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
